Diabetes Medication Use in Association with Survival among Patients of Breast, Colorectal, Lung, or Gastric Cancer

Michelle L. Baglia; Yong Cui; Tao Zheng; Gong Yang; Honglan Li; Mingrong You; Liling Xu; Harvey Murff; Yu-Tang Gao; Wei Zheng; Yong-Bing Xiang; Xiao-Ou Shu

doi:10.4143/crt.2017.591

Articles

Page Path: HOME > Cancer Res Treat > Volume 51(2); 2019 > Article

Original Article Diabetes Medication Use in Association with Survival among Patients of Breast, Colorectal, Lung, or Gastric Cancer: Michelle L. Baglia, PhD¹, Yong Cui, MD, MSPH¹, Tao Zheng, PhD², Gong Yang, MD, MPH¹, Honglan Li, MD, MSc³, Mingrong You, BA¹, Liling Xu, PhD², Harvey Murff, MD, PhD⁴, Yu-Tang Gao, MD³, Wei Zheng, MD, PhD¹, Yong-Bing Xiang, MD, MSc³, Xiao-Ou Shu, MD, PhD^1,; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2019;51(2):538-546.
DOI: https://doi.org/10.4143/crt.2017.591
Published online: July 2, 2018

¹Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA

²Tongren Hospital, Shanghai Jiao Tong University, Shanghai, China

³Shanghai Cancer Institute, Shanghai Jiao Tong University, Shanghai, China

⁴Division of General Internal Medicine, Department of Medicine, Vanderbilt University, Nashville, TN, USA

Correspondence: Xiao-Ou Shu, MD, PhD Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 600 (IMPH), Nashville, TN 37203-1738, USA
Tel: 1-615-936-0713 Fax: 1-615-936-8291 E-mail: xiao-ou.shu@vanderbilt.edu

• Received: December 14, 2017 • Accepted: June 25, 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

10,621 Views
263 Download
38 Web of Science
32 Crossref
42 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
Studies suggest that regular use of metformin may decrease cancer mortality. We investigated the association between diabetes medication use and cancer survival.
Materials and Methods
The current study includes 633 breast, 890 colorectal, 824 lung, and 543 gastric cancer cases identified from participants of two population-based cohort studies in Shanghai. Information on diabetes medication use was obtained by linking to electronic medical records. The associations between diabetes medication use (metformin, sulfonylureas, and insulin) and overall and cancer-specific survival were evaluated using time-dependent Cox proportional hazards models.
Results
After adjustment for clinical characteristics and treatment factors, use of metformin was associated with better overall survival among colorectal cancer patients (hazards ratio [HR], 0.55; 95% confidence interval [CI], 0.34 to 0.88) and for all four types of cancer combined (HR, 0.75; 95% CI, 0.57 to 0.98). Ever use of insulin was associated with worse survival for all cancer types combined (HR, 1.89; 95% CI, 1.57 to 2.29) and for the four cancer types individually. Similar associations were seen for diabetic patients. Sulfonylureas use was associated with worse overall survival for breast or gastric cancer (HR, 2.87; 95% CI, 1.22 to 6.80 and HR, 2.05; 95% CI, 1.09 to 3.84, respectively) among diabetic patients. Similar association patterns were observed between diabetes medication use and cancer-specific survival.
Conclusion
Metformin was associated with improved survival among colorectal cancer cases, while insulin use was associated with worse survival among patients of four major cancers. Further investigation on the topic is needed given the potential translational impact of these findings.
Key words: Cancer survival, Diabetes medication, Metformin

Introduction

Diabetes is associated with an increased risk of cancers, as well as overall/cancer mortality [1]. Recent studies have shown that metformin and other diabetes medications may reduce risk or mortality for some cancers [2,3], although findings are inconsistent [4].

A recent meta-analysis reported that metformin use was associated with reduced overall cancer mortality, and liver cancer and breast cancer mortality individually [4]. Overall cancer mortality was evaluated in four studies, all of which observed decreased mortality among metformin users compared to non-users [5-8], although one study’s findings did not reach statistical significance [5]. One study evaluated mortality by cancer type and found that metformin use was associated with decreased mortality from lung cancer, but observed no association with breast or colorectal cancer [8].

Fewer studies have evaluated cancer survival, rather than mortality, and its association with metformin. For breast cancer survival, one study observed improved survival among stage ≥ 2, HER2+ breast cancer patients [9], while another study found no association in survival among triple-negative breast cancer patients [10]. One previous study in colorectal cancer patients found significantly increased survival among metformin users [11]. Other recent studies, not included in the meta-analysis, were identified. One study among lung cancer patients found no significant survival benefit for metformin users when compared to either non-diabetics or diabetic non-users [12]. A study among diabetic patients with non-small cell lung cancer found significantly reduced mortality among patients with longer duration of metformin use, particularly those who began taking metformin prior to lung cancer diagnosis [13]. A study among colorectal cancer patients with and without diabetes found that metformin use was associated with better survival compared to diabetics taking other diabetes medication [14], while another study found that metformin use among diabetics was associated with better survival compared to diabetic patients taking any or no other diabetes medications [15]. A study evaluating metformin use and gastric cancer reported that the increased cumulative duration of metformin use decreased the recurrence, all-cause mortality, and cancer-specific mortality rates among gastric cancer patients with diabetes who underwent gastrectomy [16], while another study suggested that metformin use might improve overall mortality, but not cancer-specific survival [17].

Fewer studies have been published evaluating the association between cancer mortality/survival and other diabetes medications, such as sulfonylureas or insulin. One study found that sulfonylureas or insulin monotherapy in the three months prior to cancer diagnosis was associated with higher overall cancer mortality compared to non-diabetics [8]. Another study found the cumulative dose exposure to insulin was associated with lower cancer mortality among diabetic patients taking insulin [18]. Metformin users have been shown to have lower mortality rates compared to sulfonylureas or insulin users [19].

To date, epidemiologic studies on the association between diabetes medications and cancer survival are limited and the findings inconsistent. Furthermore, there is a serious concern that immortal time bias (in epidemiology, immortal time refers to a period of cohort follow-up or observation time, during which death cannot occur) may have influenced many studies that examined medication exposure, including metformin use, and cancer survival [20-22]. We report here a study of 2,890 incident cancer cases (633 breast, 890 colorectal, 824 lung, and 543 gastric) identified from participants of the Shanghai Men’s Health Study (SMHS) and the Shanghai Women’s Health Study (SWHS). Using information obtained via electronic medical records (EMR), we examined the associations between metformin, sulfonylureas, and insulin use and survival from breast, colorectal, lung, and gastric cancers with a time-dependent analytic approach.

Materials and Methods

1. Ascertainment of cancer cases

Incident cases of breast, lung, colorectal, or gastric cancer were identified from the SMHS and SWHS, two ongoing population-based cohort studies. Details of these studies have been previously described [23,24]. Briefly, Shanghai residents aged 40-70 years were recruited to the SWHS from 1996-2000 and aged 40-74 years to the SMHS from 2002-2006. Information on demographic/lifestyle factors was collected at baseline through in-person interviews via structured questionnaires by trained interviewers. Cancer occurrence information was collected via annual record linkage with the population-based Shanghai Cancer Registry supplemented by in-person surveys every 2-4 years. Matches were verified by home visits. Cancer diagnoses were verified and clinical information was extracted through review of medical charts obtained from the diagnosing hospital.

Participants with a first cancer diagnosis of colorectal cancer (International Classification of Diseases ninth edition [ICD-9] codes 153 and 154), lung cancer (ICD-9 code 162), gastric cancer (ICD-9 code 151), and breast cancer (among females only) (ICD-9 code 174) [25,26] after study enrollment were selected for this study and were sent for linkage to EMR (n=4,436). Diabetes medication use from 2004-2014 was extracted from EMR for 3,438 participants. We excluded participants diagnosed with cancer prior to 2004 due to incompleteness of EMR data collection of medication use prior to this time point (n=548), resulting in 2,890 cancer cases for the analysis.

2. Ascertainment of diabetes diagnosis and medication use

Information on diagnosis of other chronic diseases, including diabetes, was obtained through active surveys conducted every 2-4 years in both cohorts. In 2015, we linked cancer cases identified from the SWHS and SMHS to EMR data from the Changning District Health Information Center to obtain common diseases and medication use information. The data included clinic visits, laboratory tests, diagnosis, hospital discharge summary, and prescriptions. Using this data, participants were categorized by diabetes medication class (metformin, sulfonylureas, insulin, glucosidase inhibitors, thiazolidinone compounds, and Chinese hypoglycemic medicine), and whether use was initiated before and/or after cancer diagnosis. In the current study, we treat patients with either self-reported diabetes history or EMR evidence of diabetes as diabetic cases.

3. Statistical analysis

The study endpoints were death from any cause (for overall survival analyses), and cancer-specific death from breast, colorectal, lung, or gastric cancer (for relevant cancer-specific survival analyses). The censor date for event-free individuals was the date of last in-person contact or December 31, 2014 (6 months prior to the date of the most recent record linkage), whichever was most recent. For cancer-specific mortality analysis, follow-up time for patients who died of other causes was censored.

Demographic/lifestyle and clinical/treatment factors were tabulated by cancer type. The 3- and 5-year survival rates were calculated using the life table analysis method and compared using the log-rank test; 34.3% of participants had ≥ 5 years of survival time (from date of diagnosis to death or date of last follow-up). Cox proportional hazards models with age as the time scale starting at age of cancer diagnosis were used to estimate the associations of survival outcomes with use of diabetes medications of interest, including metformin, sulfonylureas, and insulin [27]. Hazard ratio (HR) refers to use versus non-use of specific diabetes medications. The proportional hazards assumptions were evaluated by checking with the Schoenfeld residuals. Stratified Cox proportional hazards models were used for some categorical covariates that did not satisfy the proportional assumption. To alleviate the concern of the immortal time bias for medication uses initiated after cancer diagnoses, those medication uses were treated as the time-dependent variables in the survival analysis [28]. The covariates adjusted for in the Cox models were sex, education, body mass index (BMI), cigarette smoking status, regular exercise, comorbidity (i.e., myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease), TNM stages of cancer, and cancer treatment (surgery, chemotherapy, and radiotherapy). Use of diabetes medications were mutually adjusted in the analysis. The analyses were conducted for each type of cancer separately and for all four types of cancer combined. Two sets of analyses were carried out: model 1—analysis included all participants of the study, and model 2—analysis included only diabetic patients. All statistical analyses were performed using SAS ver. 9.4 (SAS Institute, Cary, NC).

4. Ethical statement

All participants provided written informed consent and the study was approved by the Institutional Review Boards (IRBs) at all participating institutions.

Results

Included in the current analysis are 2,890 cancer cases: 633 breast, 890 colorectal, 824 lung, and 543 gastric. Patient characteristics by diabetes and diabetes medication use are presented in S1 Table. Over a median follow-up of 3.4 years after cancer diagnosis (interquartile range, 1.0 to 6.3 years), 1,528 deaths were documented among 2,890 patients. The 5-year survival rate by cancer type was 87.6% (breast), 58.4% (colorectal), 18.3% (lung), and 36.7% (gastric). Overall survival rate by cancer type was positively associated with education and surgery, but inversely associated with age at cancer diagnosis and TNM stage (Table 1). Among breast cancer cases, overall survival rate was inversely associated with baseline (pre-cancer diagnosis) BMI, current/former smoking status, and existing comorbidity. For colorectal cancer cases, overall survival rate was higher among those with chemotherapy, but lower among those with high baseline BMI, existing comorbidity and radiotherapy. For lung cancer cases, overall survival rate was higher among females, or those with no comorbidity and chemotherapy, but lower for current/former smokers. Among gastric cancer cases, overall survival rate was positively associated with chemotherapy (Table 1).

Diabetes status was associated with increased risk of overall and cancer-specific mortality among breast cancer cases (HR, 1.56; 95% confidence interval [CI], 1.01 to 2.43, and HR, 1.62; 95% CI, 0.98 to 2.67, respectively) after adjustment for patient and clinical characteristics. However, no such associations were detected in colorectal, lung, and gastric cancer cases (Table 2).

Among all participants (diabetics and non-diabetics) in the study, better overall survival was found among metformin users with colorectal cancer (HR, 0.55; 95% CI, 0.34 to 0.88) or when all four cancer types were combined (HR, 0.75; 95% CI, 0.57 to 0.98) (Table 3) compared to non-users. Ever use of insulin among all participants was associated with worse survival when all four cancer types were combined (HR, 1.89; 95% CI, 1.57 to 2.29) and individually for breast (HR, 1.94; 95% CI, 1.05 to 3.56), colorectal (HR, 2.60; 95% CI, 1.90 to 3.54), lung (HR, 1.43; 95% CI, 1.06 to 1.94), and gastric cancer (HR, 1.45; 95% CI, 0.99 to 2.10) (Table 3). When the analysis was restricted to diabetic patients only, the association of sulfonylureas use with worse overall survival was observed for breast or gastric cancer (HR, 2.87; 95% CI, 1.22 to 6.80 and HR, 2.05; 95% CI, 1.09 to 3.84, respectively) and for all four cancer sites combined (HR, 1.49; 95% CI, 1.09 to 2.03). The association of metformin use with better overall survival and the association of insulin use with worse overall survival were also evident in colorectal cancer and all four cancer types combined when the analysis was restricted to diabetics (Table 3).

Similar to the observed associations between diabetes medication use and overall survival, metformin use was associated with better cancer-specific survival, while ever use of insulin was associated with worse cancer-specific survival in colorectal cancer and all four cancer types combined among all participants or diabetic patients only (Table 4). An association between use of sulfonylureas with worse cancer-specific survival was also observed for all four cancer types combined (HR, 1.45; 95% CI, 1.08 to 1.94) among diabetics (Table 4).

Discussion

Metformin, a biguanide, is the most commonly used type 2 diabetes drug [29]. It improves insulin resistance by decreasing circulating levels of glucose and insulin, which may indirectly affect cancer growth [12,30]. In vivo studies have shown that mice on a control diet exhibited less antitumor activity associated with metformin compared with mice on a high energy diet, suggesting that the antitumor activity of metformin may be due to reduced endogenous insulin levels [31-33]. Metformin may also have direct anti-cancer effects, including mammalian target of rapamycin inhibition through the activation of AMP-kinase, which reduces cell growth and proliferation by slowing protein synthesis [12,34,35]. In our study, we found metformin use was associated with decreased risk of mortality among colorectal cancer patients but not in patients with breast, lung, or gastric cancers. Our finding suggests that effects of metformin use vary by cancer type; however, underlying reasons are unclear. Studies have shown that hyperinsulinemia patients with tumor expression of the insulin receptor, LKB1, and TSC2 may respond to metformin therapy while patients without these characteristics may not [34]. More studies are needed to better understand the effects of metformin therapy in different patient populations and to identify biomarkers that may predict responsiveness to metformin.

Unlike metformin, sulfonylureas and exogenous insulin increase circulating levels of insulin [36]. Insulin is known to have mitogenic properties, and increased levels of insulin may promote carcinogenesis due to insulin’s growth-promoting properties [37-39]. Previous studies have observed that patients with type 2 diabetes who were exposed to sulfonylureas and exogenous insulin had a significantly increased risk of cancer-related mortality compared with patients exposed to metformin [37]. In our study, we observed worse survival for all four cancer types among those patients who had ever used insulin, as well as for certain types of cancer, such as breast cancer and gastric cancer, among diabetic patients who took sulfonylureas. It is uncertain whether this increased risk is related to a deleterious effect of sulfonylurea and insulin or a protective effect of metformin or due to some unmeasured effect related to both choice of therapy and cancer risk. In addition, diabetic cases who use insulin are generally more severe cases than those who are only prescribed oral diabetes medications. This may also contribute to the higher mortality noted in insulin users.

Many diabetic patients in our study were taking multiple diabetes medications concurrently. Although we have mutually adjusted diabetes medication use in our analysis, we were unable to evaluate the association for monotherapy patients and had to rely on any use of the medication as the study variable due to the low number of monotherapy patients in our study population. We were unable to accurately account for length of medication use, due to the inability to capture use of medications prior to establishment of EMR. Studies that assess pharmacological factors, such as concurrent versus monotherapy medication use and dosage/duration of medication use, may better assess the association between cancer survival and diabetes medication use and potential survival bias. Finally, we were missing TNM stage information for 24% of patients included in the analyses, which may have introduced a residual confounding effect. Our study has several noteworthy strengths. The data come from large population-based studies with comprehensive data collection. Self-reported diabetes information was supplemented by EMR data, and medication use was gathered from EMR, strengthening the validity of our data.

Our study evaluated survival after cancer diagnosis, rather than mortality, allowing us to evaluate the potential survival advantage of diabetes medication use among cancer patients. Unlike most previous studies, in this study we comprehensively adjusted for a wide range of potential confounding factors. Importantly, we used time-dependent Cox proportional hazards models in the survival analysis, thus alleviating any concern of immortal time bias for medication use initiated after cancer diagnoses.

In summary, we found that use of metformin was associated with improved overall and cancer-specific survival among colorectal cancer patients. In contrast, insulin use was associated with worse survival from breast, lung, colorectal, and gastric cancers. Sulfonylurea use was associated with worse survival among breast or gastric cancer patients with diabetes. Additional investigation on the topic is needed given the potential translational impact if our findings are proven to be true.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (http://www.e-crt.org).

crt-2017-591-suppl.pdf

NOTES

Conflict of interest relevant to this article was not reported.

Acknowledgements

This work was supported by NIH grants for the SMHS [UM1 CA173640]; SWHS [UM1 CA182910] studies; State Key Project Specialized for Infectious Diseases China [2008ZX10002-015, 2012ZX-10002008-002]; and National Center for Advancing Translational Sciences [TL1TR000447 to M.L.B].

Table 1.

Demographic and clinical characteristics of cancer cases for overall survival (OS) by cancer type, Shanghai, China

	Breast cancer			Colorectal cancer			Lung cancer			Gastric cancer
	No. of deaths/participants	3-Yr/5-Yr OS rate (%)^a)	p-value	No. of deaths/participants	3-Yr/5-Yr OS rate (%)^a)	p-value	No. of deaths/participants	3-Yr/5-Yr OS rate (%)^a)	p-value	No. of deaths/participants	3-Yr/5-Yr OS rate (%)^a)	p-value
Overall survival	107/633	92.7/87.6	n/a	383/890	65.9/58.4	n/a	681/824	26.2/18.3	n/a	357/543	42.3/36.7	n/a
Sex
Female	107/633	92.7/87.6	n/a	197/477	66.4/60.0	0.27	271/340	32.1/22.6	< 0.01	135/203	40.4/35.5	0.59
Male	n/a	n/a		186/413	65.2/56.6		410/484	22.1/15.2		222/340	43.5/37.4
Education (%)
≤ High school	75/340	90.9/83.9	< 0.01	235/513	63.1/55.4	0.04	466/534	21.2/13.6	< 0.01	229/329	37.4/32.0	< 0.01
> High school	32/293	94.9/91.6		148/377	69.7/62.4		215/290	35.5/26.9		128/214	50.0/43.6
Body mass index (kg/m²)
< 25	51/365	93.2/90.1	< 0.01	224/508	65.3/58.3	0.03	464/563	26.6/18.6	0.59	208/321	44.8/38.2	0.54
25-29	44/228	93.0/85.7		131/333	69.0/60.7		179/221	25.8/19.0		131/196	38.8/35.2
≥ 30	12/40	87.5/75.0		28/49	50.6/43.1		38/40	22.5/10.0		18/26	38.5/29.9
Exercise regularly (%)
No	71/427	92.7/87.6	0.78	209/494	67.2/59.2	0.73	392/486	28.4/19.9	0.01	190/296	43.2/37.9	0.79
Yes	36/206	92.7/87.5		174/396	64.1/57.4		289/338	23.1/15.9		167/247	41.3/35.3
Smoking status
Never	102/621	93.1/87.8	0.03	256/607	65.8/58.9	0.55	295/374	32.6/23.7	< 0.01	192/296	41.6/36.5	0.87
Current/Former	5/12	75.0/75.0		127/283	65.9/57.3		386/450	20.9/13.8		165/247	43.3/36.9
Comorbidity
No	92/576	93.2/88.3	0.04	239/625	68.6/61.9	< 0.01	415/515	28.9/20.9	0.01	214/334	40.7/36.4	0.98
yes	15/57	87.7/80.3		144/265	59.5/50.7		266/309	21.7/13.8		143/209	45.0/37.2
Age at cancer diagnosis (yr)
40-49	5/52	98.1/96.2	0.01	10/24	70.8/66.7	< 0.01	22/31	41.9/35.0	< 0.01	17/28	57.1/45.9	0.03
50-59	42/280	93.6/89.5		58/189	75.6/71.7		125/173	37.6/29.2		70/120	47.4/43.1
≥ 60	60/301	91.0/84.3		315/677	63.0/54.3		534/620	22.3/14.3		270/395	39.7/34.2
TNM stage
Stage I	13/202	98.0/95.3	< 0.01	30/188	93.6/85.6	< 0.01	16/58	84.5/73.5	< 0.01	23/99	90.9/84.4	< 0.01
Stage II	41/289	95.2/91.1		58/198	79.1/72.3		41/87	59.8/52.4		73/129	51.9/44.5
Stage III	20/43	69.8/67.4		122/247	61.8/52.2		79/96	34.4/18.3		56/67	28.4/16.9
Stage IV	8/12	41.7/31.3		88/94	10.3/6.2		278/287	11.5/3.1		84/88	5.2/3.5
Unknown	25/87	90.8/76.1		85/163	55.8/49.4		267/296	16.6/12.0		121/160	30.6/26.6
Chemotherapy
No	19/81	90.1/81.7	0.08	125/236	54.6/47.4	< 0.01	280/326	20.3/15.6	< 0.01	140/198	36.9/31.5	< 0.01
Yes	88/552	93.1/88.5		258/654	69.9/62.4		401/498	30.1/20.1		217/345	45.5/39.7
Radiotherapy
No	81/497	93.8/87.7	0.55	349/837	67.4/59.6	< 0.01	545/668	27.0/19.9	0.91	350/532	42.5/36.7	0.80
Yes	26/136	89.0/87.3		34/53	41.1/39.1		136/156	23.1/11.2		7/11	36.4/36.4
Surgery
No	11/17	58.8/32.7	< 0.01	66/80	18.8/17.4	< 0.01	518/539	10.8/4.1	< 0.01	119/131	12.2/9.4	< 0.01
Yes	96/616	93.7/89.1		317/810	70.5/62.4		163/285	55.4/44.6		238/412	51.9/45.4

^a) Survival rate calculated using life table analysis method.

Table 2.

Associations between diabetes and survival from breast, colorectal, lung, and gastric cancers, Shanghai, China

	Breast		Colon or rectum		Lung		Gastric		All four sites
	No.	HR (95% CI)^a)	No.	HR (95% CI)^a)	No.	HR (95% CI)^a)	No.	HR (95% CI)^a)	No.	HR (95% CI)^a)
Overall survival
Diabetes
No	443	1.00 (reference)	598	1.00 (reference)	643	1.00 (reference)	413	1.00 (reference)	2,097	1.00 (reference)
Yes	190	1.56 (1.01-2.43)	292	0.81 (0.62-1.06)	181	0.81 (0.63-1.02)	130	1.11 (0.81-1.53)	793	0.96 (0.82-1.13)
Disease-specific survival
Diabetes
No	443	1.00 (reference)	598	1.00 (reference)	643	1.00 (reference)	413	1.00 (reference)	2,097	1.00 (reference)
Yes	190	1.62 (0.98-2.67)	292	0.80 (0.60-1.06)	181	0.83 (0.65-1.06)	130	1.03 (0.73-1.43)	793	0.91 (0.77-1.07)

HR, hazards ratio; CI, confidence interval.

^a) Adjusted for education, body mass index, smoking status, regular exercise, comorbidity, TNM stage of cancer, chemotherapy, radiotherapy, and surgery; all except breast cancer analyses additionally adjusted for sex.

Table 3.

Associations between use of diabetes medications (metformin, sulfonylureas, and insulin) and overall survival, Shanghai, China

	Cancer site
	All 4 sites combined	Breast	Colorectal	Lung	Gastric
Model I (all participants)
Events/Total	1,528/2,890	107/633	383/890	681/824	357/543
Use of metformin
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	0.75 (0.57-0.98)	0.73 (0.35-1.53)	0.55 (0.34-0.88)	0.93 (0.61-1.40)	0.95 (0.52-1.74)
Use of sulfonylureas
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	1.03 (0.82-1.30)	1.65 (0.87-3.10)	1.02 (0.69-1.52)	0.79 (0.55-1.12)	1.00 (0.60-1.68)
Use of insulin
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	1.89 (1.57-2.29)	1.94 (1.05-3.56)	2.60 (1.90-3.54)	1.43 (1.06-1.94)	1.45 (0.99-2.10)
Model II (all diabetic patients)
Events/Total	373/793	38/190	116/292	138/181	81/130
Use of metformin
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	0.74 (0.53-1.02)	0.76 (0.33-1.75)	0.51 (0.30-0.88)	1.56 (0.87-2.79)	1.01 (0.48-2.12)
Use of sulfonylureas
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	1.49 (1.09-2.03)	2.87 (1.22-6.80)	1.50 (0.93-2.41)	1.03 (0.62-1.71)	2.05 (1.09-3.84)
Use of insulin
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	1.70 (1.26-2.29)	1.36 (0.64-2.89)	4.06 (2.59-6.39)	1.15 (0.70-1.88)	1.36 (0.69-2.69)

Hazard ratios adjusted for education, body mass index, smoking status, regular exercise, comorbidity, TNM stage of cancer, chemotherapy, radiotherapy, and surgery; all except breast cancer analyses additionally adjusted for sex. During analyses, use of diabetes medications (metformin, sulfonylureas, and insulin) was also adjusted mutually in the models.

Table 4.

Associations between use of diabetes medications (metformin, sulfonylureas, and insulin) and cancer-specific survival, Shanghai, China

	Cancer site
	All 4 sites combined	Breast	Colorectal	Lung	Gastric
Model I (all participants)
Events/Total	1,408/2,890	84/633	342/890	648/824	334/543
Use of metformin
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	0.75 (0.56-1.01)	0.70 (0.29-1.70)	0.58 (0.35-0.95)	0.98 (0.64-1.49)	0.90 (0.48-1.70)
Use of sulfonylureas
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	0.97 (0.76-1.23)	1.78 (0.86-3.71)	1.00 (0.66-1.52)	0.75 (0.52-1.08)	0.91 (0.52-1.58)
Use of insulin
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	1.80 (1.48-2.21)	1.32 (0.62-2.82)	2.52 (1.81-3.51)	1.40 (1.02-1.91)	1.44 (0.98-2.14)
Model II (all diabetic patients)
Events/Total	331/793	29/190	101/292	128/181	73/130
Use of metformin
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	0.74 (0.54-1.01)	0.84 (0.32-2.20)	0.53 (0.29-0.96)	1.57 (0.86-2.56)	1.01 (0.46-2.22)
Use of sulfonylureas
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	1.45 (1.08-1.94)	2.20 (0.83-5.84)	1.59 (0.94-2.70)	0.99 (0.58-1.67)	1.76 (0.90-3.42)
Use of insulin
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	1.67 (1.27-2.19)	0.92 (0.36-2.31)	3.88 (2.32-6.47)	1.19 (0.72-1.97)	1.41 (0.68-2.92)

REFERENCES

1. Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008;300:2754–64. Article PubMed PMC
2. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One. 2012;7:e33411Article PubMed PMC
3. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2010;3:1451–61. Article PubMed
4. Zhang P, Li H, Tan X, Chen L, Wang S. Association of metformin use with cancer incidence and mortality: a meta-analysis. Cancer Epidemiol. 2013;37:207–18. Article PubMed
5. Baur DM, Klotsche J, Hamnvik OP, Sievers C, Pieper L, Wittchen HU, et al. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism. 2011;60:1363–71. Article PubMed
6. Bo S, Ciccone G, Rosato R, Villois P, Appendino G, Ghigo E, et al. Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients. Diabetes Obes Metab. 2012;14:23–9. Article PubMed
7. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010;33:322–6. Article PubMed
8. Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL. Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care. 2012;35:299–304. Article PubMed PMC
9. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol. 2012;23:1771–80. Article PubMed PDF
10. Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer. 2012;118:1202–11. Article PubMed
11. Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH, Kim WH. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer. 2012;131:752–9. Article PubMed
12. Ahmed I, Ferro A, Cohler A, Langenfeld J, Surakanti SG, Aisner J, et al. Impact of metformin use on survival in locally-advanced, inoperable non-small cell lung cancer treated with definitive chemoradiation. J Thorac Dis. 2015;7:346–55. PubMed PMC
13. Lin J, Gill A, Zahm SH, Carter CA, Shriver CD, Nations JA, et al. Metformin use and survival after non-small cell lung cancer: a cohort study in the US Military health system. Int J Cancer. 2017;141:254–63. Article PubMed PMC
14. Ramjeesingh R, Orr C, Bricks CS, Hopman WM, Hammad N. A retrospective study on the role of diabetes and metformin in colorectal cancer disease survival. Curr Oncol. 2016;23:e116–22. Article PubMed PMC
15. Paulus JK, Williams CD, Cossor FI, Kelley MJ, Martell RE. Metformin, diabetes, and survival among U.S. Veterans with colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2016;25:1418–25. Article PubMed PMC
16. Lee CK, Jung M, Jung I, Heo SJ, Jeong YH, An JY, et al. Cumulative metformin use and its impact on survival in gastric cancer patients after gastrectomy. Ann Surg. 2016;263:96–102. Article PubMed
17. Lacroix O, Couttenier A, Vaes E, Cardwell CR, De Schutter H, Robert A. Impact of metformin on gastric adenocarcinoma survival: a Belgian population based study. Cancer Epidemiol. 2018;53:149–55. Article PubMed
18. Ioacara S, Guja C, Ionescu-Tirgoviste C, Fica S, Roden M. Cancer specific mortality in insulin-treated type 2 diabetes patients. PLoS One. 2014;9:e93132Article PubMed PMC
19. Bowker SL, Yasui Y, Veugelers P, Johnson JA. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia. 2010;53:1631–7. Article PubMed
20. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007;16:241–9. Article PubMed
21. Chaiteerakij R, Petersen GM, Bamlet WR, Chaffee KG, Zhen DB, Burch PA, et al. Metformin use and survival of patients with pancreatic cancer: a cautionary lesson. J Clin Oncol. 2016;34:1898–904. Article PubMed PMC
22. Xin W, Fang L, Fang Q, Zheng X, Huang P. Effects of metformin on survival outcomes of pancreatic cancer patients with diabetes: a meta-analysis. Mol Clin Oncol. 2018;8:483–8. Article PubMed
23. Lee SA, Xu WH, Zheng W, Li H, Yang G, Xiang YB, et al. Physical activity patterns and their correlates among Chinese men in Shanghai. Med Sci Sports Exerc. 2007;39:1700–7. Article PubMed
24. Zheng W, Chow WH, Yang G, Jin F, Rothman N, Blair A, et al. The Shanghai Women's Health Study: rationale, study design, and baseline characteristics. Am J Epidemiol. 2005;162:1123–31. Article PubMed PDF
25. Centers for Disease Control and Prevention [Internet]. Atlanta, GA: Centers for Disease Control and Prevention; 2018. [cited 2018 Jun 1]. Available from: https://www.cdc.gov/nhsn/xls/icd-10-cmddc.xlsxI--CDDC
26. ICD10Data.com [Internet]. ICD10Data.com; 2018. [cited 2018 Jun 1]. Available from: http://www.icd10data.com/ICD10CM/Codes/E00-E89/E08-E13/E11-I--CDCETd
27. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol. 1997;145:72–80. Article PubMed PDF
28. Hanley JA, Foster BJ. Avoiding blunders involving 'immortal time'. Int J Epidemiol. 2014;43:949–61. Article PubMed PMC PDF
29. Belda-Iniesta C, Pernia O, Simo R. Metformin: a new option in cancer treatment. Clin Transl Oncol. 2011;13:363–7. Article PubMed
30. Howlett HC. Metformin in the management of type 2 diabetes. Diabet Med. 1989;6:179–80.
31. Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer. 2008;15:833–9. Article PubMed
32. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev. 2009;30:586–623. Article PubMed PDF
33. Cao X, Wen ZS, Wang XD, Li Y, Liu KY, Wang X. The clinical effect of metformin on the survival of lung cancer patients with diabetes: a comprehensive systematic review and meta-analysis of retrospective studies. J Cancer. 2017;8:2532–41. Article PubMed PMC
34. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med. 2011;9:33.Article PubMed PMC PDF
35. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol. 2008;110:246–50. Article PubMed
36. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29:254–8. Article PubMed
37. Barker BE, Fanger H, Farnes P. Human mammary slices in organ xulture. I. Method of culture and preliminary observations on the effect of insulin. Exp Cell Res. 1964;35:437–48. Article PubMed
38. Rosenfeld RG. Insulin-like growth factors and the basis of growth. N Engl J Med. 2003;349:2184–6. Article PubMed
39. Del Giudice ME, Fantus IG, Ezzat S, McKeown-Eyssen G, Page D, Goodwin PJ. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat. 1998;47:111–20. Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Effect of Metformin Use on Survival and Recurrence Rate of Gastric Cancer After Gastrectomy in Diabetic Patients: A Systematic Review and Meta-analysis of Observational Studies
Mansour Bahardoust, Safa Mousavi, Zahra Deylami Moezi, Mohsen Yarali, Ali Tayebi, Faranak Olamaeian, Adnan Tizmaghz
Journal of Gastrointestinal Cancer.2024; 55(1): 65. CrossRef
Antidiabetic Drugs in Breast Cancer Patients
Wojciech Garczorz, Agnieszka Kosowska, Tomasz Francuz
Cancers.2024; 16(2): 299. CrossRef
Association of metformin and statin uses with the prognosis of colon cancer: a meta-analysis
Yanyan Xu, Hao Che, Jiang Liu, Pingjiang Ye
European Journal of Cancer Prevention.2024; 33(5): 414. CrossRef
Metformin in combination with chemotherapy increases apoptosis in gastric cancer cells and counteracts senescence induced by chemotherapy
Katia Vázquez‑Ibarra, Josefina Sánchez López, Tomás Pineda Razo, José Cruz Lozano, Brenda Ortiz‑Tamayo, Luis Palafox‑Mariscal, Rosa González Arreola, Juan González‑García, Pablo Ortiz-Lazareno
Oncology Letters.2024;[Epub] CrossRef
Investigating the relationship between insulin use and all-cause mortality, breast cancer mortality, and recurrence risk in diabetic patients with breast cancer: A comprehensive systematic review and meta-analysis
Marina V. Loktionova, Mahdi Mohammadian, Roya Choopani, Soleiman Kheiri, Abdollah Mohammadian-Hafshejani, Kathleen Bennett
PLOS ONE.2024; 19(12): e0314565. CrossRef
A Mathematical Model of the Disruption of Glucose Homeostasis in Cancer Patients
Noah Salentine, Jonathan Doria, Chinh Nguyen, Gabriella Pinter, Shizhen Emily Wang, Peter Hinow
Bulletin of Mathematical Biology.2023;[Epub] CrossRef
Effect of Metformin on the Prognosis of Gastric Cancer Patients with Type 2 Diabetes Mellitus: A Meta-Analysis Based on Retrospective Cohort Studies
Lingna Li, Jianing Huang, Tongmin Huang, Jie Yao, Yeyuan Zhang, Meiling Chen, Haojie Shentu, Haiying Lou, Flavia Prodam
International Journal of Endocrinology.2023; 2023: 1. CrossRef
Shared Lifestyle-Related Risk Factors of Cardiovascular Disease and Cancer: Evidence for Joint Prevention
Farzad Masoudkabir, Noushin Mohammadifard, Arya Mani, Andrew Ignaszewski, Margot K. Davis, Golnaz Vaseghi, Marjan Mansourian, Christopher Franco, Carolyn Gotay, Nizal Sarrafzadegan, Francesco Giallauria
The Scientific World Journal.2023; 2023: 1. CrossRef
Diabetes Mellitus and Gastric Cancer: Correlation and Potential Mechanisms
Li Wang, Zhe Zhang, Eusebio Chiefari
Journal of Diabetes Research.2023; 2023: 1. CrossRef
Perspectives of metformin use in endometrial cancer and other gynaecological malignancies
Bartłomiej Barczyński, Karolina Frąszczak, Jan Kotarski
Journal of Drug Targeting.2022; 30(4): 359. CrossRef
Type 2 Diabetes and all-cause mortality among Spanish women with breast cancer
L. Fernández-Arce, N. Robles-Rodríguez, A. Fernández-Feito, A. Llaneza-Folgueras, A. I. Encinas-Muñiz, A. Lana
Cancer Causes & Control.2022; 33(2): 271. CrossRef
Diabetes and Colorectal Cancer Risk: Clinical and Therapeutic Implications
Guan-Hua Yu, Shuo-Feng Li, Ran Wei, Zheng Jiang, Eusebio Chiefari
Journal of Diabetes Research.2022; 2022: 1. CrossRef
Systemic Evaluation of the Effect of Diabetes Mellitus on Breast Cancer in a Mouse Model
Nana Wei, Jinmiao Lu, Zhibing Lin, Xiaoyu Wang, Mengmeng Cai, Shengyao Jiang, Xiaoyu Chen, Shilan Zhu, Dong Zhang, Li Cui
Frontiers in Oncology.2022;[Epub] CrossRef
The Association of Metformin, Other Antidiabetic Medications and Statins on the Prognosis of Rectal Cancer in Patients with Type 2 Diabetes: A Retrospective Cohort Study
Sami Erkinantti, Ari Hautakoski, Reijo Sund, Martti Arffman, Elina Urpilainen, Ulla Puistola, Esa Läärä, Arja Jukkola, Peeter Karihtala
Biomolecules.2022; 12(9): 1301. CrossRef
Metformin protects against diabetes-induced heart injury and dunning prostate cancer model
BB Bayrak, P Koroglu, O Karabulut Bulan, R Yanardag
Human & Experimental Toxicology.2021; 40(2): 297. CrossRef
Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy
Alejandro Schcolnik-Cabrera, Alma Chavez-Blanco, Guadalupe Dominguez-Gomez, Mandy Juarez, Ariana Vargas-Castillo, Rafael Isaac Ponce-Toledo, Donna Lai, Sheng Hua, Armando R. Tovar, Nimbe Torres, Delia Perez-Montiel, Jose Diaz-Chavez, Alfonso Duenas-Gonzal
Scientific Reports.2021;[Epub] CrossRef
Repurposing metformin for the treatment of gastrointestinal cancer
Ademar Dantas Cunha Júnior, Arinilda Campos Bragagnoli, Felipe Osório Costa, José Barreto Campello Carvalheira
World Journal of Gastroenterology.2021; 27(17): 1883. CrossRef
Improved prognosis in gastric adenocarcinoma among metformin users in a population-based study
Jiaojiao Zheng, Giola Santoni, Shao-Hua Xie, Jesper Lagergren
British Journal of Cancer.2021; 125(2): 277. CrossRef
The Relationship between Diabetes Mellitus and Gastric Cancer and the Potential Benefits of Metformin: An Extensive Review of the Literature
Chin-Hsiao Tseng
Biomolecules.2021; 11(7): 1022. CrossRef
Potential intrinsic subtype dependence on the association between metformin use and survival in surgically resected breast cancer: a Korean national population-based study
Byoung Hyuck Kim, Moon-June Cho, Jeanny Kwon
International Journal of Clinical Oncology.2021; 26(11): 2004. CrossRef
Progress in understanding of relationship between diabetes and colorectal cancer
Guan-Hua Yu, Zheng Jiang
World Chinese Journal of Digestology.2021; 29(23): 1323. CrossRef
The effect of metformin on gastric cancer in patients with type 2 diabetes: a systematic review and meta-analysis
Y. Shuai, C. Li, X. Zhou
Clinical and Translational Oncology.2020; 22(9): 1580. CrossRef
The right place for metformin today
Guntram Schernthaner, Gerit-Holger Schernthaner
Diabetes Research and Clinical Practice.2020; 159: 107946. CrossRef
Suppressive effects of metformin on colorectal adenoma incidence and malignant progression
Min Deng, Siqin Lei, Dongdong Huang, Hui Wang, Shuli Xia, Enping Xu, Yihua Wu, Honghe Zhang
Pathology - Research and Practice.2020; 216(2): 152775. CrossRef
Preventative and Therapeutic Effects of Metformin in Gastric Cancer: A New Contribution of an Old Friend

Jing Zhang, Liping Wen, Quan Zhou, Kuifeng He, Lisong Teng
Cancer Management and Research.2020; Volume 12: 8545. CrossRef
Does Roux-en-Y Construction Really Bring Benefit of Type 2 Diabetes Mellitus Remission After Gastrectomy in Patients with Gastric Cancer? A Systematic Review and Meta-Analysis
Dong Peng, Yu-Xi Cheng, Wei Zhang
Diabetes Therapy.2020; 11(12): 2863. CrossRef
Prognosis of Patients with Colorectal Cancer with Diabetes According to Medication Adherence: A Population-Based Cohort Study
Sunho Choe, Joonki Lee, Ji Won Park, Seung-Yong Jeong, Young Min Cho, Byung-Joo Park, Aesun Shin
Cancer Epidemiology, Biomarkers & Prevention.2020; 29(6): 1120. CrossRef
The combination of orlistat, lonidamine and 6‑diazo‑5‑oxo‑L‑norleucine induces a quiescent energetic phenotype and limits substrate flexibility in colon cancer cells
Alejandro Schcolnik‑Cabrera, Alma Chavez‑Blanco, Guadalupe Dominguez‑Gomez, Mandy Juarez, Donna Lai, Sheng Hua, Armando Tovar, Jose Diaz‑Chavez, Alfonso Duenas‑Gonzalez
Oncology Letters.2020; 20(3): 3053. CrossRef
Diabetes Mellitus and Colon Carcinogenesis: Expectation for Inhibition of Colon Carcinogenesis by Oral Hypoglycemic Drugs
Junichi Kato, Yohei Shirakami, Masahito Shimizu
Gastrointestinal Disorders.2019; 1(2): 273. CrossRef
Use of Antihypertensive Medications and Survival Rates for Breast, Colorectal, Lung, or Stomach Cancer
Yong Cui, Wanqing Wen, Tao Zheng, Honglan Li, Yu-Tang Gao, Hui Cai, Mingrong You, Jing Gao, Gong Yang, Wei Zheng, Yong-Bing Xiang, Xiao-Ou Shu
American Journal of Epidemiology.2019; 188(8): 1512. CrossRef
Effects of propofol and sevoflurane on blood glucose, hemodynamics, and inflammatory factors of patients with type�2 diabetes mellitus and gastric cancer
Jinhui Liu, Li Yang
Oncology Letters.2019;[Epub] CrossRef
A cohort study of antihyperglycemic medication exposure and survival in patients with gastric cancer
Audrius Dulskas, Ausvydas Patasius, Donata Linkeviciute-Ulinskiene, Lina Zabuliene, Giedre Smailyte
Aging.2019; 11(17): 7197. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Diabetes Medication Use in Association with Survival among Patients of Breast, Colorectal, Lung, or Gastric Cancer

Cancer Res Treat. 2019;51(2):538-546. Published online July 2, 2018

DOI: https://doi.org/10.4143/crt.2017.591

XML Download

Top of article

Abstract
Introduction
Materials and Methods
Results
Discussion
Electronic Supplementary Material
NOTES
REFERENCES

Diabetes Medication Use in Association with Survival among Patients of Breast, Colorectal, Lung, or Gastric Cancer

	Breast cancer			Colorectal cancer			Lung cancer			Gastric cancer
	No. of deaths/participants	3-Yr/5-Yr OS rate (%)^a)	p-value	No. of deaths/participants	3-Yr/5-Yr OS rate (%)^a)	p-value	No. of deaths/participants	3-Yr/5-Yr OS rate (%)^a)	p-value	No. of deaths/participants	3-Yr/5-Yr OS rate (%)^a)	p-value
Overall survival	107/633	92.7/87.6	n/a	383/890	65.9/58.4	n/a	681/824	26.2/18.3	n/a	357/543	42.3/36.7	n/a
Sex
Female	107/633	92.7/87.6	n/a	197/477	66.4/60.0	0.27	271/340	32.1/22.6	< 0.01	135/203	40.4/35.5	0.59
Male	n/a	n/a		186/413	65.2/56.6		410/484	22.1/15.2		222/340	43.5/37.4
Education (%)
≤ High school	75/340	90.9/83.9	< 0.01	235/513	63.1/55.4	0.04	466/534	21.2/13.6	< 0.01	229/329	37.4/32.0	< 0.01
> High school	32/293	94.9/91.6		148/377	69.7/62.4		215/290	35.5/26.9		128/214	50.0/43.6
Body mass index (kg/m²)
< 25	51/365	93.2/90.1	< 0.01	224/508	65.3/58.3	0.03	464/563	26.6/18.6	0.59	208/321	44.8/38.2	0.54
25-29	44/228	93.0/85.7		131/333	69.0/60.7		179/221	25.8/19.0		131/196	38.8/35.2
≥ 30	12/40	87.5/75.0		28/49	50.6/43.1		38/40	22.5/10.0		18/26	38.5/29.9
Exercise regularly (%)
No	71/427	92.7/87.6	0.78	209/494	67.2/59.2	0.73	392/486	28.4/19.9	0.01	190/296	43.2/37.9	0.79
Yes	36/206	92.7/87.5		174/396	64.1/57.4		289/338	23.1/15.9		167/247	41.3/35.3
Smoking status
Never	102/621	93.1/87.8	0.03	256/607	65.8/58.9	0.55	295/374	32.6/23.7	< 0.01	192/296	41.6/36.5	0.87
Current/Former	5/12	75.0/75.0		127/283	65.9/57.3		386/450	20.9/13.8		165/247	43.3/36.9
Comorbidity
No	92/576	93.2/88.3	0.04	239/625	68.6/61.9	< 0.01	415/515	28.9/20.9	0.01	214/334	40.7/36.4	0.98
yes	15/57	87.7/80.3		144/265	59.5/50.7		266/309	21.7/13.8		143/209	45.0/37.2
Age at cancer diagnosis (yr)
40-49	5/52	98.1/96.2	0.01	10/24	70.8/66.7	< 0.01	22/31	41.9/35.0	< 0.01	17/28	57.1/45.9	0.03
50-59	42/280	93.6/89.5		58/189	75.6/71.7		125/173	37.6/29.2		70/120	47.4/43.1
≥ 60	60/301	91.0/84.3		315/677	63.0/54.3		534/620	22.3/14.3		270/395	39.7/34.2
TNM stage
Stage I	13/202	98.0/95.3	< 0.01	30/188	93.6/85.6	< 0.01	16/58	84.5/73.5	< 0.01	23/99	90.9/84.4	< 0.01
Stage II	41/289	95.2/91.1		58/198	79.1/72.3		41/87	59.8/52.4		73/129	51.9/44.5
Stage III	20/43	69.8/67.4		122/247	61.8/52.2		79/96	34.4/18.3		56/67	28.4/16.9
Stage IV	8/12	41.7/31.3		88/94	10.3/6.2		278/287	11.5/3.1		84/88	5.2/3.5
Unknown	25/87	90.8/76.1		85/163	55.8/49.4		267/296	16.6/12.0		121/160	30.6/26.6
Chemotherapy
No	19/81	90.1/81.7	0.08	125/236	54.6/47.4	< 0.01	280/326	20.3/15.6	< 0.01	140/198	36.9/31.5	< 0.01
Yes	88/552	93.1/88.5		258/654	69.9/62.4		401/498	30.1/20.1		217/345	45.5/39.7
Radiotherapy
No	81/497	93.8/87.7	0.55	349/837	67.4/59.6	< 0.01	545/668	27.0/19.9	0.91	350/532	42.5/36.7	0.80
Yes	26/136	89.0/87.3		34/53	41.1/39.1		136/156	23.1/11.2		7/11	36.4/36.4
Surgery
No	11/17	58.8/32.7	< 0.01	66/80	18.8/17.4	< 0.01	518/539	10.8/4.1	< 0.01	119/131	12.2/9.4	< 0.01
Yes	96/616	93.7/89.1		317/810	70.5/62.4		163/285	55.4/44.6		238/412	51.9/45.4

	Breast		Colon or rectum		Lung		Gastric		All four sites
	No.	HR (95% CI)^a)	No.	HR (95% CI)^a)	No.	HR (95% CI)^a)	No.	HR (95% CI)^a)	No.	HR (95% CI)^a)
Overall survival
Diabetes
No	443	1.00 (reference)	598	1.00 (reference)	643	1.00 (reference)	413	1.00 (reference)	2,097	1.00 (reference)
Yes	190	1.56 (1.01-2.43)	292	0.81 (0.62-1.06)	181	0.81 (0.63-1.02)	130	1.11 (0.81-1.53)	793	0.96 (0.82-1.13)
Disease-specific survival
Diabetes
No	443	1.00 (reference)	598	1.00 (reference)	643	1.00 (reference)	413	1.00 (reference)	2,097	1.00 (reference)
Yes	190	1.62 (0.98-2.67)	292	0.80 (0.60-1.06)	181	0.83 (0.65-1.06)	130	1.03 (0.73-1.43)	793	0.91 (0.77-1.07)

	Cancer site
	All 4 sites combined	Breast	Colorectal	Lung	Gastric
Model I (all participants)
Events/Total	1,528/2,890	107/633	383/890	681/824	357/543
Use of metformin
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	0.75 (0.57-0.98)	0.73 (0.35-1.53)	0.55 (0.34-0.88)	0.93 (0.61-1.40)	0.95 (0.52-1.74)
Use of sulfonylureas
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	1.03 (0.82-1.30)	1.65 (0.87-3.10)	1.02 (0.69-1.52)	0.79 (0.55-1.12)	1.00 (0.60-1.68)
Use of insulin
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	1.89 (1.57-2.29)	1.94 (1.05-3.56)	2.60 (1.90-3.54)	1.43 (1.06-1.94)	1.45 (0.99-2.10)
Model II (all diabetic patients)
Events/Total	373/793	38/190	116/292	138/181	81/130
Use of metformin
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	0.74 (0.53-1.02)	0.76 (0.33-1.75)	0.51 (0.30-0.88)	1.56 (0.87-2.79)	1.01 (0.48-2.12)
Use of sulfonylureas
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	1.49 (1.09-2.03)	2.87 (1.22-6.80)	1.50 (0.93-2.41)	1.03 (0.62-1.71)	2.05 (1.09-3.84)
Use of insulin
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	1.70 (1.26-2.29)	1.36 (0.64-2.89)	4.06 (2.59-6.39)	1.15 (0.70-1.88)	1.36 (0.69-2.69)

	Cancer site
	All 4 sites combined	Breast	Colorectal	Lung	Gastric
Model I (all participants)
Events/Total	1,408/2,890	84/633	342/890	648/824	334/543
Use of metformin
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	0.75 (0.56-1.01)	0.70 (0.29-1.70)	0.58 (0.35-0.95)	0.98 (0.64-1.49)	0.90 (0.48-1.70)
Use of sulfonylureas
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	0.97 (0.76-1.23)	1.78 (0.86-3.71)	1.00 (0.66-1.52)	0.75 (0.52-1.08)	0.91 (0.52-1.58)
Use of insulin
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	1.80 (1.48-2.21)	1.32 (0.62-2.82)	2.52 (1.81-3.51)	1.40 (1.02-1.91)	1.44 (0.98-2.14)
Model II (all diabetic patients)
Events/Total	331/793	29/190	101/292	128/181	73/130
Use of metformin
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	0.74 (0.54-1.01)	0.84 (0.32-2.20)	0.53 (0.29-0.96)	1.57 (0.86-2.56)	1.01 (0.46-2.22)
Use of sulfonylureas
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	1.45 (1.08-1.94)	2.20 (0.83-5.84)	1.59 (0.94-2.70)	0.99 (0.58-1.67)	1.76 (0.90-3.42)
Use of insulin
Never use	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)	1.00 (ref.)
Ever use	1.67 (1.27-2.19)	0.92 (0.36-2.31)	3.88 (2.32-6.47)	1.19 (0.72-1.97)	1.41 (0.68-2.92)

Table 1. Demographic and clinical characteristics of cancer cases for overall survival (OS) by cancer type, Shanghai, China

Survival rate calculated using life table analysis method.

Table 2. Associations between diabetes and survival from breast, colorectal, lung, and gastric cancers, Shanghai, China

HR, hazards ratio; CI, confidence interval.

Adjusted for education, body mass index, smoking status, regular exercise, comorbidity, TNM stage of cancer, chemotherapy, radiotherapy, and surgery; all except breast cancer analyses additionally adjusted for sex.

Table 3. Associations between use of diabetes medications (metformin, sulfonylureas, and insulin) and overall survival, Shanghai, China

Table 4. Associations between use of diabetes medications (metformin, sulfonylureas, and insulin) and cancer-specific survival, Shanghai, China